RESTRUCTURING CHARGES

12 Months Ended

Dec. 31, 2024

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, asset impairments, and related consulting fees. The following reflects our restructuring activity (in millions):


	Year Ended
	December 31, 2024
	Supply Chain Reinvention		HRA Pharma Integration		Project Energize		Other Initiatives		Total
Beginning balance	$	0.7	$	6.8	$	2.9	$	1.8	$	12.2
Additional charges	14.5		—		95.2		0.4		110.1
Payments	(12.6)		(5.2)		(59.7)		(1.3)		(78.8)
Non-cash adjustments	(0.3)		—		(10.5)		0.1		(10.7)
Ending balance	$	2.3	$	1.6	$	27.9	$	1.0	$	32.8


	Year Ended
	December 31, 2023
	Supply Chain Reinvention		HRA Pharma Integration		Project Energize		Other Initiatives		Total
Beginning balance	$	2.2	$	13.3	$	—	$	4.3	$	19.8
Additional charges	28.0		4.2		7.4		2.6		42.2
Payments	(13.4)		(10.9)		(4.5)		(4.6)		(33.4)
Non-cash adjustments	(16.1)		0.2		—		(0.5)		(16.4)
Ending balance	$	0.7	$	6.8	$	2.9	$	1.8	$	12.2


	Year Ended
	December 31, 2022
	Supply Chain Reinvention		Other Initiatives		Total
Beginning balance	$	—	$	6.9	$	6.9
Additional charges	24.3		18.2		42.5
Payments	(22.1)		(7.7)		(29.8)
Non-cash adjustments	—		0.2		0.2
Ending balance	$	2.2	$	17.6	$	19.8

The charges incurred during the year ended December 31, 2024 were primarily associated with actions taken on Project Energize activities associated with employee separation, consulting fees and lease exit costs. The charges incurred during the year ended December 31, 2023 were primarily associated with actions taken on our multi-year supply chain restructuring, including an asset impairment of $16.1 million, Project Energize and HRA integration activities. The charges incurred during the year ended December 31, 2022 were primarily associated with actions taken on supply chain restructuring and HRA integration activities.

Of the amount recorded during the year ended December 31, 2024, $53.8 million was related to our CSCI segment and $28.9 million related to our CSCA segment, and $27.4 million was related to our Unallocated segment. For all segments, amounts were due primarily to Project Energize. Of the amount recorded during the year ended December 31, 2023, $21.4 million was related to our CSCI segment, due primarily to supply chain restructuring and HRA Pharma integration initiatives and $13.0 million was related to our CSCA segment, also due primarily to supply chain restructuring initiatives. Of the amount recorded during the year ended December 31, 2022, $29.4 million was related to our CSCI segment, due primarily to supply chain restructuring and HRA integration initiatives, and $2.5 million was allocated to our CSCA segment, due primarily to actions taken to streamline the organization.

There were no other material restructuring programs in any of the periods presented. All charges are recorded in Restructuring expense on the Consolidated Financial Statements. The remaining $32.8 million liability for employee severance benefits is expected to be paid mostly within the next year.